Filing Details
- Accession Number:
- 0000904454-13-000695
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-13 18:21:37
- Reporting Period:
- 2013-06-11
- Filing Date:
- 2013-06-13
- Accepted Time:
- 2013-06-13 18:21:37
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1262104 | Mei Pharma Inc. | MEIP | Pharmaceutical Preparations (2834) | 510407811 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1509160 | Vivo Ventures Fund Vii, L.p. | 575 High Street Suite 201 Palo Alto CA 94301 | No | No | Yes | No | |
1538309 | Vivo Ventures Vii Affiliates Fund, L.p. | 575 High Street Suite 201 Palo Alto CA 94301 | No | No | Yes | No | |
1565020 | Vivo Ventures Vii, Llc | 575 High Street Suite 201 Palo Alto CA 94301 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2013-06-11 | 236,273 | $7.80 | 3,987,095 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
Footnotes
- The number reported excludes 420,000 shares issuable upon conversion of warrants that were reported in Table I of the Form 3 filed on December 21, 2012.
- Includes 3,902,051 shares held of record by Vivo Ventures Fund VII, L.P., and 85,044 shares held of record by Vivo Ventures VII Affiliates Fund, L.P. (together, the "Vivo VII Funds"). Vivo Ventures VII, LLC (the "Vivo VII GP"), as the sole general partner of both of the Vivo VII Funds, may be deemed to beneficially own the Common Stock of the Issuer owned by the Vivo VII Funds. Vivo VII GP disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein.